Background:
Cancer complications or treatment-related toxicities frequently necessitate urgent evaluation and intervention, often resulting in emergency department (ED) visits and hospitalisations.
To address this, in January 2023, we launched a nurse-led Rapid Access Clinic Expansion (RACE) service, designed to offer a streamlined model for patients undergoing cancer treatment and reduce unnecessary ED presentations.
Aim:
To describe the characteristics, interventions and outcomes for patients who accessed RACE.
Methods:
A retrospective review was conducted of all patients accessing the RACE service from 23 January 2023 to 6 June 2024. Demographics, presenting symptoms, interventions and outcomes were recorded and data analysed using descriptive statistics.
Results:
RACE received 628 telephone calls and managed 337 patients in the study period. 81% (507/628) of calls were managed entirely as outpatients. For most of the calls (530/628, 84%) ED presentation was avoided.
The remaining 98 calls (16%) were appropriately directed to present to the ED.
Patients made on average 1.86 calls (Median 1, Range 1-13)
The median age was 64 years (Range 6-93 years; Standard Deviation 13 years).
Patients accessing the service were receiving systemic intravenous or oral therapies.
The most frequent presenting primary malignancies included:
♦ breast,
♦ colorectal,
♦ upper-gastrointestinal,
♦ gynaecological and,
♦ genitourinary.
Pain, fatigue and decline in performance status were the most frequent presenting symptoms.
All calls were triaged according to the United Kingdom Oncology Nursing Society (UKONS) criteria:
♦ 47.9% self-care advice,
♦ 23.6% clinical review within 24 hours and,
♦28.5% urgent clinical assessment.
Majority of calls 59% (371/628) were managed with phone advice.
Patients managed in the outpatient setting were scripted with required medications or admitted to the day unit for intravenous infusions.
Conclusions:
The RACE service provided streamlined and efficient outpatient care for oncology patients undergoing treatment, whilst reducing ED presentations.
It has been widely accepted by cancer care staff and patients.